Report Summaries

« Back
  Cellceutix :Where Eagles dare
Deep Dive (MDD16093001)
Aug 26, 2016  |  Price : $ 1250 BUY NOW  |  United States

The release of a new research report on Cellceutix Corporation (OTCQB: CTIX).  Cellceutix is a clinical stage biopharmaceutical company based in Beverly, Massachusetts developing innovative therapies with oncology, dermatology, antibiotic, and anti-inflammatory applications.

The 31-page report provides an in-depth analysis of the Cellceutix pipeline of drugs in development, intellectual property, key drivers, upcoming milestones and a sum of parts valuation.  The report takes a detailed look at development and clinical research of Brilacidin and its multiple target indications (e.g. infectious disease, palliative care, gastrointestinal disease, dermal conditions); Prurisol as a new oral treatment for plaque psoriasis; Kevetrin for solid tumors; and preclinical research being conducted by Cellceutix.  Our comprehensive analysis includes a view of the competitive landscape of drugs marketed and in development by others to deliver an unbiased outlook as to the current and future market opportunity and fair value of the Cellceutix pipeline.

Please download the complete report.  We would appreciate any queries / comments from your side

For Subscribers : Download the full document - PDF File (31, 1279 KB)
Tags & Keywords : Cellceutix, CTIX, Anti-infective, Brilacidin, ABSSSI, Prurisol, Kevetrin, Oral Mucositis, Ulcerative proctitis, proctosigmoiditis, Ovarian Cancer, Psoriasis

MP ADVISORS


© MP Advisors 2013 All rights reserved.